Is Thymosin Alpha-1 Legal in Washington? How to Access It Legally

HealthRX.com

No US approval or compounding route exists for it

Print or save as PDF

Key numbers

  • 4 yes and 17 noFDA advisory committee votes on adding thymosin alpha-1 to the pharmacy bulks list, December 2024Source: fda.gov, as cited Nov 7, 2026
  • 1.6 mgZadaxin vial strength sold outside the US; not interchangeable with bulk powderSource: fda.gov, as cited Nov 7, 2026
  • 4 weeksLength of the Italian Zadaxin course after the first flu vaccination dose; not a US-approved doseSource: fda.gov, as cited Nov 7, 2026
  • FDA approval / None; no US application exists [1]
  • Advisory committee vote / 4 yes, 17 no, December 4, 2024 [5]
  • Pharmacy bulks list / In none of the three categories, May 14, 2026 [6]
  • Outsourcing-facility list / Category 3, nominated without adequate support [7]
  • HHS peptide policy / Not among its six peptides, October 2026 draft [2]
  • Approved elsewhere / Italy, India and Hong Kong; Zadaxin 1.6 mg vials [1]
  • Washington statutes / RCW 18.64 pharmacy, RCW 18.71 physicians [3][4]
  • Anti-doping / Not named on WADA's 2026 Prohibited List [8]

Is thymosin alpha-1 FDA-approved?

No. A Drugs@FDA search found no US application for thymosin alpha-1, also called thymalfasin [1]. FDA's December 2024 review notes four US orphan drug designations, but an orphan designation is not an approval [1].

It is a 28-amino-acid peptide originally isolated from thymosin fraction 5, a thymus extract; thymalfasin is the synthetic version with the same sequence [1]. Zadaxin, the finished injection sold outside the US at 1.6 mg per vial, is not interchangeable with bulk powder [1].

What do FDA's compounding lists say?

On FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, thymosin alpha-1 appears in none of the three categories [6]. On the list for outsourcing facilities, updated March 21, 2025, it sits in category 3, 'nominated without adequate support' [7]. FDA's category 1 policy, generally no action against compounders when its conditions are met, does not apply to it [6][7].

On December 4, 2024 FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate, and FDA proposed that it not be added to the pharmacy bulks list [5]. Members who voted no cited no compelling evidence of clinical effectiveness and safety [5].

It also appears in the 'nominated but withdrawn' table on FDA's page about bulk substances that may present significant safety risks, having come off category 2 when the nominators withdrew [9]. FDA's posted concerns remain: significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information the agency called inadequate [9].

It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy, which covers BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [2].

What does Washington law say?

Washington requires a license to practice pharmacy under RCW 18.64, a chapter that also includes a section on responsibility for drug purity and compounding [3]. Physicians are licensed under RCW 18.71 [4]. These are general licensing chapters; the federal status above is what determines whether a thymosin alpha-1 product exists to be dispensed.

Questions worth asking

Choose the questions you want to keep

Where is it approved outside the US?

FDA's December 2024 review lists national authorizations in Italy, India and Hong Kong [1]. In Italy, Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; in India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].

The Italian label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks from the first vaccination, repeated from week 8 to week 12. It says the product is not for children and is contraindicated in pregnancy and breastfeeding, with caution in people with allergies or autoimmune disease [1]. No US-approved dose exists [1].

Does the anti-doping list name it?

No. Thymosin alpha-1 is not named on WADA's 2026 Prohibited List [8]. WADA does name thymosin-beta-4 and its derivatives such as TB-500 under S2.3, growth factors, which is a different peptide [8].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. Does an orphan drug designation count as an FDA approval?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is thymosin alpha-1 legal in Washington?
No FDA-approved product exists, and no FDA or HHS action allowing its compounding was found [1][2]. Washington licenses pharmacists under RCW 18.64 and physicians under RCW 18.71 [3][4].
Is thymosin alpha-1 on FDA's compounding lists?
It is in none of the three categories on the list for state-licensed pharmacies and physicians, and category 3, nominated without adequate support, on the outsourcing-facility list [6][7].
Is it approved in other countries?
FDA lists national authorizations in Italy, India and Hong Kong, and the European Medicines Agency holds only an orphan designation for hepatocellular carcinoma [1].
Does WADA ban thymosin alpha-1?
It is not named on WADA's 2026 Prohibited List, while thymosin-beta-4 and TB-500 are named under S2.3 [8].
Show all 9 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in Washington? How to Access It Legally